Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 49

Sort by

Sort Order Select

Journal Articles

Impact of Prior Response to Blinatumomab on Outcomes of Brexucabtagene Autoleucel (Brexu-cel) in Adult Patients with Relapsed or Refractory (r/r) B-Cell Acute Lymphoblastic Leukemia (B-ALL): Results from the Real-World Outcomes Collaborative of CAR-T in Adult ALL (ROCCA)

Blood (2023) 142 (Supplement 1): 2119.

https://doi.org/10.1182/blood-2023-182915

Published: 2023

Journal Articles

Brexucabtagene Autoleucel in Adults with Relapsed/Refractory B-Cell ALL: Outcomes and Novel Insights from the Real-World Outcomes Collaborative of CAR T in Adult ALL (ROCCA)

Gregory W Roloff, Ibrahim Aldoss, Noam E. Kopmar, Chenyu Lin, Simone E. Dekker, Vishal K Gupta, Nikeshan Jeyakumar, Timothy E O'Connor, Amy Zhang, Katharine Miller, Kaitlyn C Dykes, Mohamed Ahmed, Hector Zambrano, Danielle Bradshaw, Santiago Mercadal, Marc Schwartz, Sean Tracy, Bhagirathbhai Dholaria, Michal Kubiak, Akash Mukherjee, Navneet Majhail, Minoo Battiwalla, Luke Mountjoy, Shahbaz A. Malik, John Mathews, Paul Shaughnessy, Aaron C. Logan, Abdullah Ladha, George Yaghmour, Anjali S. Advani, Maryann Stefan, Caitlin Guzowski, Rasmus T. Hoeg, Talal Hilal, Jozal Moore, Kristen M. O'Dwyer, Stephanie B. Tsai, Joshua Sasine, Melhem M. Solh, Catherine J. Lee, Vamsi K. Kota, Divya Koura, Muthu Veeraputhiran, Betsy Blunk, Jessica T. Leonard, Veronika Bachanova, Wendy Stock, Ahmed Galal, Vinod Pullarkat, Ryan D Cassaday, Bijal D. Shah, Rawan Faramand, Lori S. Muffly

Blood (2023) 142 (Supplement 1): 1030.

https://doi.org/10.1182/blood-2023-182531

Published: 2023

Journal Articles

Bridging Therapy in Adults with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia Receiving Standard of Care Brexucabtagene Autoleucel: Results from the Real-World Outcomes Collaborative of CAR T in Adult ALL (ROCCA)

Chenyu Lin, Stephanie B. Tsai, Gregory W Roloff, Amy Zhang, Ibrahim Aldoss, Noam E. Kopmar, Simone E. Dekker, Nikeshan Jeyakumar, Vishal K Gupta, Timothy E O'Connor, Kaitlyn C Dykes, Mohamed Ahmed, Bhagirathbhai Dholaria, Hector Zambrano, Danielle Bradshaw, Aaron C. Logan, Sean Tracy, Michal Kubiak, Melhem M. Solh, Santiago Mercadal, Marc Schwartz, Akash Mukherjee, Minoo Battiwalla, Paul Shaughnessy, Navneet Majhail, Luke Mountjoy, Shahbaz A. Malik, John Mathews, Abdullah Ladha, Anjali S. Advani, Maryann Stefan, Caitlin Guzowski, Rasmus T. Hoeg, Talal Hilal, Jozal Moore, Kristen M. O'Dwyer, Joshua Sasine, Catherine J. Lee, Vamsi K. Kota, Divya Koura, Muthu Veeraputhiran, Betsy Blunk, Jessica T. Leonard, Caspian H. Oliai, Veronika Bachanova, Wendy Stock, Vinod Pullarkat, Ryan D Cassaday, Katharine Miller, Lori S. Muffly, Ahmed Galal, Bijal D. Shah, Rawan Faramand

Blood (2023) 142 (Supplement 1): 3502.

https://doi.org/10.1182/blood-2023-182380

Published: 2023

Journal Articles

Toxicity Profile of Brexucabtagene Autoleucel (brexu-cel; CD19-directed CAR T-cell therapy) in Adult Patients (pts) with Relapsed/Refractory (R/R) B-Cell Acute Lymphoblastic Leukemia (B-ALL): Results from a Multicenter Real-World Outcomes Study

Noam E. Kopmar, Ted Gooley, Gregory W Roloff, Ibrahim Aldoss, Chenyu Lin, Simone E. Dekker, Vishal K Gupta, Nikeshan Jeyakumar, Timothy O'connor, Kaitlyn C Dykes, Mohamed Ahmed, Hector Zambrano, Danielle Bradshaw, Santiago Mercadal, Marc Schwartz, Sean Tracy, Bhagirathbhai Dholaria, Michal Kubiak, Akash Mukherjee, Navneet Majhail, Minoo Battiwalla, Luke Mountjoy, Shabaz Malik, Paul Shaughnessy, John Mathews, Aaron C. Logan, Abdullah Ladha, George Yaghmour, Anjali S. Advani, Maryann Stefan, Caitlin Guzowski, Rasmus T. Hoeg, Talal Hilal, Jozal Moore, Kristen M. O'Dwyer, Stephanie B. Tsai, Joshua Sasine, Melhem M. Solh, Catherine J. Lee, Vamsi K. Kota, Divya Koura, Muthu Veeraputhiran, Betsy Blunk, Jessica T. Leonard, Caspian H. Oliai, Veronika Bachanova, Wendy Stock, Ahmed Galal, Vinod Pullarkat, Bijal D. Shah, Rawan Faramand, Lori S. Muffly, Ryan D Cassaday

Blood (2023) 142 (Supplement 1): 522.

https://doi.org/10.1182/blood-2023-185107

Published: 2023

Journal Articles

The Impact of Social Determinants of Health on Brexucabtagene Autoleucel Outcomes in Adults with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia

Timothy E O'Connor, Chenyu Lin, Gregory W Roloff, Amy Zhang, Ibrahim Aldoss, Rawan Faramand, Noam E. Kopmar, Kaitlyn C Dykes, Nikeshan Jeyakumar, Simone E. Dekker, Vishal K Gupta, Mohamed Ahmed, Aaron C. Logan, Hector Zambrano, Danielle Bradshaw, Santiago Mercadal, Marc Schwartz, Sean Tracy, Michal Kubiak, Akash Mukherjee, Navneet Majhail, Minoo Battiwalla, Luke Mountjoy, Shabaz Malik, John Mathews, Paul Shaughnessy, Abdullah Ladha, George Yaghmour, Anjali S. Advani, Maryann Stefan, Caitlin Guzowski, Rasmus T. Hoeg, Talal Hilal, Jozal Moore, Joshua Sasine, Melhem M. Solh, Catherine J. Lee, Vamsi K. Kota, Divya Koura, Muthu Veeraputhiran, Betsy Blunk, Jessica T. Leonard, Caspian H. Oliai, Veronika Bachanova, Wendy Stock, Ryan D Cassaday, Bijal D. Shah, Katharine Miller, Lori S. Muffly, Ahmed Galal, Stephanie B. Tsai, Bhagirathbhai Dholaria

Blood (2023) 142 (Supplement 1): 671.

https://doi.org/10.1182/blood-2023-182566

Published: 2023

Journal Articles

The Impact of Inotuzumab Ozogamicin (InO) Treatment on Brexucabtagene Autoleucel (Brexu-cel) Outcomes in Adults with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia (B-ALL)

Ibrahim Aldoss, Gregory W Roloff, Anjali S. Advani, Noam E. Kopmar, Chenyu Lin, Simone E. Dekker, Vishal K Gupta, Nikeshan Jeyakumar, Timothy E O'Connor, Amy Zhang, Katharine Miller, Kaitlyn C Dykes, Mohamed Ahmed, Hector Zambrano, Danielle Bradshaw, Santiago Mercadal, Marc Schwartz, Sean Tracy, Bhagirathbhai Dholaria, Michal Kubiak, Akash Mukherjee, Navneet Majhail, Minoo Battiwalla, Luke Mountjoy, Shahbaz A. Malik, John Mathews, Paul Shaughnessy, Aaron C. Logan, Abdullah Ladha, George Yaghmour, Maryann Stefan, Caitlin Guzowski, Rasmus T. Hoeg, Talal Hilal, Jozal Moore, Kristen M. O'Dwyer, Stephanie B. Tsai, Joshua Sasine, Melhem M. Solh, Catherine J. Lee, Vamsi K. Kota, Divya Koura, Muthu Veeraputhiran, Betsy Blunk, Jessica T. Leonard, Caspian H. Oliai, Veronika Bachanova, Wendy Stock, Ahmed Galal, Vinod Pullarkat, Ryan D Cassaday, Bijal D. Shah, Rawan Faramand, Lori S. Muffly

Blood (2023) 142 (Supplement 1): 4877.

https://doi.org/10.1182/blood-2023-182404

Published: 2023

Journal Articles

Genomic Data Improves Prognostic Stratification in Adult T-Cell Acute Lymphoblastic Leukemia Patients Enrolled in Measurable Residual Disease-Oriented Trials

Blood (2021) 138 (Supplement 1): 3486.

https://doi.org/10.1182/blood-2021-148263

Published: 2021

Journal Articles

Ponatinib and Chemotherapy in Adults with De Novo Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia. Final Results of Ponalfil Clinical Trial

Josep-Maria Ribera, Olga Garcia, Jordi Ribera, Pau Montesinos, Isabel Cano, Pilar Martínez, Jordi Esteve, Daniel Esteban, María García-Fortes, Natalia Alonso, José González-Campos, Arancha Bermúdez, Anna Torrent, Eulàlia Genescà, Santiago Mercadal, Joaquín Martínez-López, Ramon Garcia-Sanz

Blood (2021) 138 (Supplement 1): 1230.

https://doi.org/10.1182/blood-2021-148310

Published: 2021

Journal Articles

Safety and Effectiveness of Idelalisib in Patients with Double-Refractory Follicular Lymphoma: A Pan-European Cohort of 242 Patients

Emmanuel Gyan, Maria Chiara Tisi, Francesco Merli, Luca Baldini, Francesco Di Raimondo, Santiago Mercadal, Benedetta Puccini, Elisabeth Vandenberghe, Ka Lung Wu, Anthony Boland, Rikisha Shah Gupta, Anna van Troostenburg, Carolyn Dunnill, Heribert Ramroth, Nishanthan Rajakumaraswamy, Gilles Salles

Blood (2021) 138 (Supplement 1): 1350.

https://doi.org/10.1182/blood-2021-146066

Published: 2021

Journal Articles

Phase 1/2a Clinical Trial of BI-1206, a Monoclonal Antibody to Fcγriib, in Combination with Rituximab in Subjects with Indolent B-Cell Non-Hodgkin Lymphoma That Has Relapsed or Is Refractory to Rituximab

Ingrid Karlsson, Susanne Gertsson, Suzanne Kilany, Marie Borggren, Pau Abrisqueta, Ana Carneiro, Raul Cordoba, Hans Hagberg, Mats Jerkeman, Santiago Mercadal, Jonathon B. Cohen, Juan-Manuel Sancho, Ingrid Teige, Linda Mårtensson, Björn Frendéus, Andres McAllister

Blood (2021) 138 (Supplement 1): 1354.

https://doi.org/10.1182/blood-2021-147452

Published: 2021

Journal Articles

Chemotherapy or allogeneic transplantation in high-risk Philadelphia chromosome–negative adult lymphoblastic leukemia

Josep-Maria Ribera, Mireia Morgades, Juana Ciudad, Pau Montesinos, Jordi Esteve, Eulàlia Genescà, Pere Barba, Jordi Ribera, Irene García-Cadenas, María José Moreno, Daniel Martínez-Carballeira, Anna Torrent, Pilar Martínez-Sánchez, Silvia Monsalvo, Cristina Gil, Mar Tormo, María Teresa Artola, Marta Cervera, José González-Campos, Carlos Rodríguez, Arancha Bermúdez, Andrés Novo, Beatriz Soria, Rosa Coll, María-Luz Amigo, Aurelio López-Martínez, Rosa Fernández-Martín, Josefina Serrano, Santiago Mercadal, Antònia Cladera, Alberto Giménez-Conca, María-Jesús Peñarrubia, Eugènia Abella, Ferran Vall-llovera, Jesús-María Hernández-Rivas, Antoni Garcia-Guiñon, Juan-Miguel Bergua, Beatriz de Rueda, María-José Sánchez-Sánchez, Alfons Serrano, María Calbacho, Natalia Alonso, Jose-Ángel Méndez-Sánchez, Raimundo García-Boyero, Matxalen Olivares, Susana Barrena, Lurdes Zamora, Isabel Granada, Ludovic Lhermitte, Evarist Feliu, Alberto Orfao

Blood (2021) 137 (14): 1879–1894.

https://doi.org/10.1182/blood.2020007311

Published: 2021

Includes: Supplemental data

Journal Articles

Efficacy and safety results from CheckMate 140, a phase 2 study of nivolumab for relapsed/refractory follicular lymphoma

Philippe Armand, Ann Janssens, Giuseppe Gritti, John Radford, John Timmerman, Antonio Pinto, Santiago Mercadal Vilchez, Peter Johnson, David Cunningham, John P. Leonard, Scott J. Rodig, Patricia Martín-Regueira, Anne Sumbul, Selda Samakoglu, Hao Tang, Stephen M. Ansell

Blood (2021) 137 (5): 637–645.

https://doi.org/10.1182/blood.2019004753

Published: 2021

Includes: Supplemental data

Journal Articles

17-BI-1206-02 Phase 1/2a Clinical Trial of BI-1206, a Monoclonal Antibody to Fcgriib, in Combination with Rituximab in Subjects with Indolent B-Cell Non-Hodgkin Lymphoma That Has Relapsed or Is Refractory to Rituximab

Mats Jerkeman, MD PhD, Andres McAllister, MD PhD, Carl Roos, Marie Lindell Andersson, Ingrid Karlsson, PhD, Marie Borggren, PhD, Pau Abrisqueta, MD PhD, Ana Carneiro, MD PhD, Raul Cordoba, MD PhD, Hans Hagberg, MD, Santiago Mercadal, MD, Ingrid Teige, PhD, Björn Frendéus, PhD

Blood (2020) 136 (Supplement 1): 36–37.

https://doi.org/10.1182/blood-2020-140219

Published: 2020

Journal Articles

Ponatinib and Chemotherapy in Young Adults with De Novo Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia. Results of Ponalfil Clinical Trial after Completion of Recruitment

Josep-Maria Ribera, Olga García, Pau Montesinos, MD PhD, Pilar Martinez, MD, Jordi Esteve, Daniel Esteban, María José Moreno, MD, Natalia Alonso, José González-Campos, MD, Arancha Bermúdez, MD, Anna Torrent, Joaquin Martinez-Lopez, MD, Santiago Mercadal, MD, Ramon Garcia-Sanz

Blood (2020) 136 (Supplement 1): 29–30.

https://doi.org/10.1182/blood-2020-137489

Published: 2020

Journal Articles

Safety Profile of Idelalisib in Patients with Refractory Follicular Lymphoma: Interim Analysis of a Noninterventional Study

Gilles Salles, MD PhD, Ka Lung Wu, MD PhD, Sofya Kovalchuk, MD, Santiago Mercadal, MD, Annalisa Chiarenza, MD PhD, Ruth Pettengell, MD, Elisabeth Vandenberghe, MD, Paolo Corradini, MD, Susana Carvalho, MD, Christophe De Belder, MSc, Rikisha Shah Gupta, MPH, Anna van Troostenburg, MD, Nishanthan Rajakumaraswamy, MD, Heribert Ramroth, PhD

Blood (2020) 136 (Supplement 1): 48–50.

https://doi.org/10.1182/blood-2020-137607

Published: 2020

Journal Articles

Idelalisib for Relapsed/Refractory Follicular Lymphoma: Retrospective Study from Spanish Lymphoma Group Geltamo (GELT-IDE-2018-02)

Blood (2019) 134 (Supplement_1): 5249.

https://doi.org/10.1182/blood-2019-125921

Published: 2019

Journal Articles

Rituximab and Specific Therapy for Patients with Burkitt's Leukemia and Lymphoma. Results of the BURKIMAB14 Trial from the Spanish Pethema and Geltamo Groups in 80 Patients

Blood (2019) 134 (Supplement_1): 2584.

https://doi.org/10.1182/blood-2019-125683

Published: 2019

Journal Articles

Post-Remission Treatment with Chemotherapy or Allogeneic Hematopoietic Stem Cell Transplantation (alloHSCT) in Adult Patients with High-Risk (HR) Philadelphia Chromosome-Negative (Ph-neg) Acute Lymphoblastic Leukemia (ALL) According to Their Minimal Residual Disease (MRD). Final Results of the Pethema ALL-HR-11 Trial

Blood (2019) 134 (Supplement_1): 826.

https://doi.org/10.1182/blood-2019-123613

Published: 2019

Journal Articles

Characteristics and Outcome of Early T Cell Precursor ALL (ETP-ALL) Patients Treated with High-Risk Spanish Pethema Protocols

Blood (2018) 132 (Supplement 1): 1553.

https://doi.org/10.1182/blood-2018-99-114559

Published: 2018

Journal Articles

Validation of the NCCN-IPI and the Geltamo-IPI in a Large Cohort of Patients Diagnosed of Diffuse Large B-Cell Lymphoma (DLBCL) Treated with R-CHOP/R-CHOP-like in a Single Institution

Maria Queralt Salas Gay, MD, Santiago Mercadal, MD, Eva Domingo Domenech, MD, Ana C Oliveira, MD PhD, Maite Encuentra, Fina Climent, MD PhD, Cristina Baca Cano, MD, Marcio Andrade-Campos, MD PhD, Esmeralda De la Banda, MD, Carmen Aguilera, Alberto Fernandez de Sevilla, MD PhD, Anna Sureda, Eva González-Barca, MD PhD

Blood (2017) 130 (Supplement 1): 4151.

https://doi.org/10.1182/blood.V130.Suppl_1.4151.4151

Published: 2017

NARROW

Impact of Prior Response to Blinatumomab on Outcomes of Brexucabtagene Autoleucel (Brexu-cel) in Adult Patients with Relapsed or Refractory (r/r) B-Cell Acute Lymphoblastic Leukemia (B-ALL): Results from the Real-World Outcomes Collaborative of CAR-T in Adult ALL (ROCCA)

Brexucabtagene Autoleucel in Adults with Relapsed/Refractory B-Cell ALL: Outcomes and Novel Insights from the Real-World Outcomes Collaborative of CAR T in Adult ALL (ROCCA)

Bridging Therapy in Adults with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia Receiving Standard of Care Brexucabtagene Autoleucel: Results from the Real-World Outcomes Collaborative of CAR T in Adult ALL (ROCCA)

Toxicity Profile of Brexucabtagene Autoleucel (brexu-cel; CD19-directed CAR T-cell therapy) in Adult Patients (pts) with Relapsed/Refractory (R/R) B-Cell Acute Lymphoblastic Leukemia (B-ALL): Results from a Multicenter Real-World Outcomes Study

The Impact of Social Determinants of Health on Brexucabtagene Autoleucel Outcomes in Adults with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia

The Impact of Inotuzumab Ozogamicin (InO) Treatment on Brexucabtagene Autoleucel (Brexu-cel) Outcomes in Adults with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia (B-ALL)

Genomic Data Improves Prognostic Stratification in Adult T-Cell Acute Lymphoblastic Leukemia Patients Enrolled in Measurable Residual Disease-Oriented Trials

Ponatinib and Chemotherapy in Adults with De Novo Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia. Final Results of Ponalfil Clinical Trial

Safety and Effectiveness of Idelalisib in Patients with Double-Refractory Follicular Lymphoma: A Pan-European Cohort of 242 Patients

Phase 1/2a Clinical Trial of BI-1206, a Monoclonal Antibody to Fcγriib, in Combination with Rituximab in Subjects with Indolent B-Cell Non-Hodgkin Lymphoma That Has Relapsed or Is Refractory to Rituximab

Chemotherapy or allogeneic transplantation in high-risk Philadelphia chromosome–negative adult lymphoblastic leukemia

Efficacy and safety results from CheckMate 140, a phase 2 study of nivolumab for relapsed/refractory follicular lymphoma

17-BI-1206-02 Phase 1/2a Clinical Trial of BI-1206, a Monoclonal Antibody to Fcgriib, in Combination with Rituximab in Subjects with Indolent B-Cell Non-Hodgkin Lymphoma That Has Relapsed or Is Refractory to Rituximab

Ponatinib and Chemotherapy in Young Adults with De Novo Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia. Results of Ponalfil Clinical Trial after Completion of Recruitment

Safety Profile of Idelalisib in Patients with Refractory Follicular Lymphoma: Interim Analysis of a Noninterventional Study

Idelalisib for Relapsed/Refractory Follicular Lymphoma: Retrospective Study from Spanish Lymphoma Group Geltamo (GELT-IDE-2018-02)

Rituximab and Specific Therapy for Patients with Burkitt's Leukemia and Lymphoma. Results of the BURKIMAB14 Trial from the Spanish Pethema and Geltamo Groups in 80 Patients

Characteristics and Outcome of Early T Cell Precursor ALL (ETP-ALL) Patients Treated with High-Risk Spanish Pethema Protocols

Validation of the NCCN-IPI and the Geltamo-IPI in a Large Cohort of Patients Diagnosed of Diffuse Large B-Cell Lymphoma (DLBCL) Treated with R-CHOP/R-CHOP-like in a Single Institution

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only